168 related articles for article (PubMed ID: 15205208)
41. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Calvo E; Chen VJ; Marshall M; Ohnmacht U; Hynes SM; Kumm E; Diaz HB; Barnard D; Merzoug FF; Huber L; Kays L; Iversen P; Calles A; Voss B; Lin AB; Dickgreber N; Wehler T; Sebastian M
Invest New Drugs; 2014 Oct; 32(5):955-68. PubMed ID: 24942404
[TBL] [Abstract][Full Text] [Related]
42. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A
Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma.
Li BS; Gong HY; Huang W; Yi Y; Zhang ZC; Li HS; Wang ZT; Yu JM
Dis Esophagus; 2011 May; 24(4):251-7. PubMed ID: 21073623
[TBL] [Abstract][Full Text] [Related]
44. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
[TBL] [Abstract][Full Text] [Related]
45. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
[TBL] [Abstract][Full Text] [Related]
46. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Shi SB; Hu RH; Qi JL; Tang XY; Tian J; Li R; Chang CX
Med Oncol; 2013; 30(2):550. PubMed ID: 23576138
[TBL] [Abstract][Full Text] [Related]
47. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
Hanauske AR; Lahn M; Musib LC; Weigang-Köhler K; Yilmaz E; Graefe T; Kuenen B; Thornton D; McNealy P; Giaccone G
Ann Oncol; 2009 Sep; 20(9):1565-1575. PubMed ID: 19487488
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
Gilbert J; Murphy B; Dietrich MS; Henry E; Jordan R; Counsell A; Wirth P; Yarbrough WG; Slebos RJ; Chung CH
Cancer; 2012 Feb; 118(4):1007-13. PubMed ID: 21766301
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
[TBL] [Abstract][Full Text] [Related]
51. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA
Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331
[TBL] [Abstract][Full Text] [Related]
52. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
[TBL] [Abstract][Full Text] [Related]
53. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
[TBL] [Abstract][Full Text] [Related]
55. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
56. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
Hanauske AR; Dumez H; Piccart M; Yilmaz E; Graefe T; Gil T; Simms L; Musib L; Awada A
Invest New Drugs; 2009 Aug; 27(4):356-65. PubMed ID: 18956139
[TBL] [Abstract][Full Text] [Related]
57. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
[TBL] [Abstract][Full Text] [Related]
58. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.
Argiris A; Karamouzis MV; Smith R; Kotsakis A; Gibson MK; Lai SY; Kim S; Branstetter BF; Shuai Y; Romkes M; Wang L; Grandis JR; Ferris RL; Johnson JT; Heron DE
Ann Oncol; 2011 Nov; 22(11):2482-2488. PubMed ID: 21363880
[TBL] [Abstract][Full Text] [Related]
59. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
60. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
Li KM; Rivory LP; Clarke SJ
Br J Cancer; 2007 Oct; 97(8):1071-6. PubMed ID: 17912246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
